RB1 and neoplasm: These pathways, often intensified by mutations in genes like TP53, RB1, and MYC, underline the challenges in treating GEP-NECs, as they adapt quickly to therapeutic pressures, necessitating advanced strategies like combination therapies, targeting multiple aspects of tumor growth and survival [121].